Pfizer, Inc.

Pfizer, Inc.

27.40
USD
-0.14
(-0.51%)
0.71EPS
40.27P/E
162.56BMarket Cap
Feb 02Next Earn
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
7.57
7.82
7.91
8.68
8.8
6.95
7.35
7.5
14.51
18.04
10.55
11.23
11.01
11.17
Basic EPS, GAAP
3.23
1.44
1.13
1.18
3.57
1.9
2.88
1.65
3.92
5.59
0.38
1.42
1.37
0.71
Free Cash Flow per Basic Share
2.38
2.44
2.14
2.33
2.44
2.33
1.82
2.1
5.33
4.64
0.85
1.74
1.6
2.07
Dividend per Share
0.97
1.04
1.12
1.2
1.28
1.36
1.44
1.52
1.56
1.6
1.64
1.68
1.72
1.72
Book Value per Share
11.92
11.33
10.48
9.81
11.92
11.09
11.41
11.36
13.74
17.03
15.77
15.56
15.21
15.61
Tangible Book Value per Share
-0.88
-0.95
-3.87
-7.84
-5.59
-4.41
-3.44
-2.63
0.51
0.16
-7.73
-6.31
-6.77
-4.99
Basic Weighted Avg Shares
6,813
6,346
6,176
6,089
5,970
5,872
5,569
5,555
5,601
5,608
5,643
5,664
5,683
5,694
Sales/Revenue/Turnover
51,584
49,605
48,851
52,824
52,546
40,825
40,905
41,651
81,288
101,175
59,554
63,627
62,579
63,624
Operating Margin (%)
31.73
27.21
26.56
25.95
26.78
16.48
17.87
22.84
29.16
37.67
7.42
23.48
27.82
26.13
Depreciation Expense
6,410
5,537
5,157
5,757
6,269
6,150
5,755
4,681
5,191
5,064
6,290
7,013
6,592
6,499
Net Income, GAAP
22,003
9,135
6,960
7,215
21,308
11,153
16,026
9,159
21,979
31,372
2,119
8,031
7,771
4,033
Effective Tax Rate (%)
27.4
25.49
22.2
13.45
- -
- -
5.15
5.26
7.62
9.58
- -
- -
- -
4.37
Profit Margin (%)
42.65
18.42
14.25
13.66
40.55
27.32
39.18
21.99
27.04
31.01
3.56
12.62
12.42
6.34
Working Capital
32,878
34,008
14,405
7,834
10,714
18,068
-4,501
9,147
17,022
9,121
-4,461
7,363
5,914
13,283
LT Debt
30,462
31,541
27,446
30,399
32,666
32,429
34,650
35,571
34,757
31,925
60,499
56,703
60,807
59,997
Total Equity
76,620
71,622
64,998
59,840
71,656
63,758
63,447
63,473
77,462
95,916
89,288
88,497
86,775
89,301
Return on Invested Capital (%)
9.86
8.07
7.1
6.64
- -
- -
9.61
5.4
16.16
25.65
- -
- -
- -
3.12
Return on Capital (%)
19.77
9.14
7.46
8.07
- -
- -
15.95
9.72
21.39
26.47
- -
- -
- -
4.31
Return on Common Equity (%)
27.94
12.38
10.24
11.62
32.58
16.56
25.33
14.5
31.3
36.3
2.29
9.06
8.9
4.44

Capital Structure

USD

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
ST Debt
3,890
2,699
2,674
LT Borrowings
59,840
60,495
59,997
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
5,699
5,699
5,700
Market Capitalization
160,028
137,243
162,564

Working Capital

USD

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
Total Current Assets
42,822
41,358
45,009
Cash, Cash Equivalents & STI
13,075
11,698
14,272
Accounts Receivable, Net
12,585
12,490
14,192
Inventories
10,667
9,945
10,022
Total Current Liabilities
34,348
32,646
31,726
Payables & Accruals
7,636
7,685
4,508
ST Debt
3,890
2,699
2,674
Deferred Revenue
- -
- -
- -

Growth Rates

USD

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
3.65%
7.22%
-1.95%
Free Cash Flow
15.28%
31.94%
-7.73%
Net Income, GAAP
51.74%
73.04%
-3.24%
Sales/Revenue/Turnover
7.1%
16.73%
-1.65%
Total Cash Common Dividend
3.49%
2.97%
2.72%

Quarterly Revenue

USD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
14,878
13,283
17,701
17,764
63,627
2025
13,715
14,653
16,654
17,557
62,579
2026
14,450
15,034
16,583
- -
- -

Quarterly Earnings Per Share

USD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.55
0.01
0.79
0.07
1.42
2025
0.52
0.51
0.62
-0.29
1.37
2026
0.47
-0.04
0.57
- -
- -

Quarterly Dividends Per Share

USD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.42
0.42
0.42
0.42
1.68
2025
0.43
0.43
0.43
0.43
1.72
2026
0.43
0.43
0.43
- -
- -

Company Description

CEO
Albert Bourla
Full Time Employees
75,000
Sector
Health technology
Industry
Pharmaceuticals: major
Address
66 Hudson Boulevard East New York NY United States 10001-2192
IPO Date
Jan 17, 1944
Website
pfizer.com
Business
Pfizer Inc. (NYSE: PFE) develops, manufactures, and markets biopharmaceutical products worldwide, focusing on oncology, vaccines, internal medicine, inflammation and immunology, and rare diseases. The company offers a broad portfolio including oncology drugs such as Ibrance (palbociclib), Xtandi (enzalutamide), Padcev (enfortumab vedotin), Elrexfio (elranatamab), Bosulif (bosutinib), Braftovi (encorafenib), Lorbrena (lorlatinib), Talzenna (talazoparib), and Tivdak (tisotumab vedotin); vaccines like Comirnaty (COVID-19 mRNA vaccine), Prevnar 13/20 (pneumococcal conjugate vaccines), Abrysvo (RSV vaccine), and Penbraya (meningococcal vaccine); cardiovascular and metabolic treatments including Eliquis (apixaban), Vyndaqel/Vyndamax (tafamidis), and Norvasc (amlodipine); primary care products such as Zavzpret (zavegepant), Chantix (varenicline), and Litfulo (ritlecitinib); antivirals like Paxlovid (nirmatrelvir/ritonavir); and consumer brands including Advil, ChapStick, and Robitussin. Founded in 1849 by Charles Pfizer and Charles F. Erhart and headquartered at 235 East 42nd Street in Manhattan, New York City, Pfizer operates manufacturing and research facilities globally across North America, Europe, Asia, and Latin America, serving healthcare providers, governments, and patients in over 100 countries. In recent developments, Pfizer completed the acquisition of Metsera in November 2025 for an initial enterprise value of $4.9 billion plus a contingent value right, adding clinical-stage obesity and cardiometabolic candidates including oral and injectable incretins; new products and acquired launches contributed $7.3 billion in incremental revenue through Q3 2025; and the company plans $10-15 billion in business development investments for 2025, emphasizing early-stage assets and collaborations, particularly with Chinese biotechs via its Ignite platform.

Company News

  • Lilly vs. Pfizer: Which Drugmaker Has Stronger Growth Prospects?

  • 5 High-Yield Dividend Stocks Retirees Can Buy for Under $50 a Share

  • Investors Heavily Search Pfizer Inc. (PFE): Here is What You Need to Know

  • 4 Dividend Stocks Wall Street Gave Up On With Balance Sheets Built to Recover

  • Pfizer Yields 6.25%. These 3 Dividend Stocks Pay More Than a 1-Year Treasury Bill

  • 4 Yield Traps Paying Over 6% That Retirees Should Watch Out For

  • PFE Inks $2.6B Licensing Deal With Chinese Biotech for CAR-T Therapies

  • Can New Products and Acquisitions Revive Pfizer's Growth Story?

  • Forget JEPI: 4 High-Yield Dividend Stocks Retirees Should Own Instead

  • 4 S&P 500 Dividend Stocks Paying Shareholders More Than Their Free Cash Flow

  • Pfizer Will Pay Its 352nd Straight Quarterly Dividend on Dec. 7. Here's What It Would Take to Break the Streak.

  • Pfizer: The Patent Cliff Fears Are Overblown

  • 4 Dividend Stocks Yielding Over 6% That Fit a Roth IRA

  • 3 High-Yield Dividend Stocks Down Nearly 30% or More in 5 Years

  • Pfizer Enters into Exclusive Licensing Agreement with Starna Therapeutics for Autoimmune Diseases

  • Pfizer: Strong Growth Momentum And Attractive Valuation Support A Strong Buy

  • Wall Street Forgot These 3 Dividend Stocks — Now They Pay Over 5%

  • Johnson & Johnson vs. Pfizer: Consistency vs.

  • 5 Safe High-Yield Dividend Stocks Boomers Should Buy Before Year-End

  • 5 “Forever Income” Dividend Stocks Yielding 5% and More for Boomers